Charles A. McWherter
2021
In 2021, Charles A. McWherter earned a total compensation of $1.1M as President of R&D at Cymabay Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $169,168 |
|---|---|
| Option Awards | $522,334 |
| Salary | $436,000 |
| Other | $3,963 |
| Total | $1,131,465 |
McWherter received $522.3K in option awards, accounting for 46% of the total pay in 2021.
McWherter also received $169.2K in non-equity incentive plan, $436K in salary and $4K in other compensation.
Rankings
In 2021, Charles A. McWherter's compensation ranked 8,366th out of 12,415 executives tracked by ExecPay. In other words, McWherter earned more than 32.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,366 out of 12,415 | 33rd |
Division Manufacturing | 3,704 out of 5,505 | 33rd |
Major group Chemicals And Allied Products | 1,648 out of 2,375 | 31st |
Industry group Drugs | 1,466 out of 2,096 | 30th |
Industry Pharmaceutical Preparations | 1,092 out of 1,546 | 29th |
Source: SEC filing on April 19, 2023.
McWherter's colleagues
We found four more compensation records of executives who worked with Charles A. McWherter at Cymabay Therapeutics in 2021.
News
Cymabay Therapeutics CEO Sujal Shah's 2022 pay rises 16% to $2.6M
April 19, 2023
Cymabay Therapeutics CEO Sujal Shah's 2021 pay slips 16% to $2.2M
April 26, 2022
Cymabay Therapeutics CEO Sujal Shah's 2019 pay jumps 32% to $2.6M
May 15, 2020
Cymabay Therapeutics General Counsel Paul Quinlan receives $3M in 2018
April 26, 2019